Depression in schizophrenia: Recognition and management in the USA

Schizophrenia Research

Volumn 47, Issue 2-3, 2001, Pages 185-197

  Siris, Samuel G ^a   Addington, Donald ^b   Azorin, Jean Michel ^c   Falloon, Ian R H ^d   Gerlach, Jes ^e   Hirsch, Steven R ^f  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b FOOTHILLS HOSPITAL   (Canada)

^c HÔPITAL SAINTE MARGUERITE   (France)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

^e Sct Hans Hospital   (Denmark)

^f IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Adjunctive therapies; Assessment; Depression; Diagnosis; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; CLOZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; AWARENESS; CLINICAL PRACTICE; CONTROLLED STUDY; DEPRESSION; ELECTROCONVULSIVE THERAPY; FAMILY; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHIATRIST; PSYCHOTHERAPY; QUESTIONNAIRE; SCHIZOPHRENIA; SUICIDE; UNITED STATES;

ANTIDEPRESSIVE AGENTS; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMANS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTHERAPY; QUESTIONNAIRES; SCHIZOPHRENIA; UNITED STATES;

EID: 0035280835     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(00)00135-3     Document Type: Article

References (36)

1. A depression rating scale for schizophrenics
2. Assessing depression in schizophrenia: The Calgary Depression Scale
3. Specificity of the Calgary Depression Scale for schizophrenia
4. Schizophrenia, a life-shorting disease
5. Practice guidelines for the treatment of patients with schizophrenia
6. Long-term treatment of mood disorders in schizophrenia
7. Schizophrenics kill themselves too: A review of risk factors for suicide
8. Imipramine-flupenthixol decanoate interaction
9. Depression and social adjustment among chronic schizophrenic outpatients
10. Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man
11. A survey of practising psychiatrists' views on the treatment of agoraphobia
12. Prodromal symptoms and prevention of relapse in schizophrenia
13. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
14. Antidepressants in 'depressed' schizophrenic inpatients: A controlled trial
15. Depressive symptoms in the course of schizophrenia
16. Interaction between antidepressants and perphenazine in psychiatric patients
17. Interactions of chlorpromazine and nortriptyline in patients with schizophrenia
18. Postpsychotic depression in schizophrenia
19. Conditions predisposing to suicide: A review
20. A path analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: A re-evaluation of the North American risperidone study
21. Antidepressant usage in schizophrenia
22. Depressive syndromes in first admission patients with schizophrenic disorders: The extent, phenomenology, correlates and change over six months
23. Relationship between depression and suicidal behaviour in schizophrenia
24. Depression in chronic schizophrenia
25. Suicidal behaviour in chronic schizophrenia: A follow up study
26. Course of schizophrenia in different countries: Some results of a WHO international comparative 5-year follow-up study
27. Diagnosis of secondary depression in schizophrenia: Implications for DSM-IV
28. The use of antidepressant edication in schizophrenia
29. Assessment and treatment of depression in schizophrenia
30. Maintenance imipramine therapy for secondary depression in schizophrenia
31. Depression and schizophrenia
32. Depression in schizophrenia: Perspective in the era of "atypical" antipsychotic agents
33. Adjunctive imipramine for a broader group of post-psychotic depressions in schizophrenia
34. Ziprasidone: A novel antipsychotic with unique pharmacology and therapeutic potential
35. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
36. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia